Exploring Windtree Therapeutics, Inc. (WINT) Investor Profile: Who’s Buying and Why?

Have you ever wondered who is investing in Windtree Therapeutics, Inc. (WINT), and more importantly, why? With a recent stock price of $1.08 as of April 21, 2025, and analysts predicting a potential surge to an average price of $3.658 in 2025, with highs of $7.25, understanding the investor landscape is crucial. Is it institutional players like Renaissance Technologies Llc, UBS Group AG and Geode Capital Management, Llc holding a total of 319,322 shares, or is it insiders and retail investors driving the market? Delve into the dynamics of Windtree Therapeutics' investor profile to uncover the motivations and strategies behind those backing this biopharmaceutical company, especially considering their reported net loss of $1.8 million for 2024 and a strategic shift towards revenue-generating acquisitions.

Windtree Therapeutics, Inc. (WINT) Who Invests in Windtree Therapeutics, Inc. (WINT) and Why?

Understanding the investor profile of Windtree Therapeutics, Inc. (WINT) involves examining the various types of investors, their motivations, and the strategies they employ. This insight is crucial for current and potential investors, as well as for the company itself, to gauge market sentiment and make informed decisions.

Key Investor Types

The investor base of Windtree Therapeutics, Inc. (WINT) can be categorized into several key types:

• Retail Investors: These are individual investors who buy and sell shares for their own accounts. Their investment decisions are often influenced by news, market trends, and personal investment goals.
• Institutional Investors: These include entities such as mutual funds, pension funds, insurance companies, and investment firms that manage large sums of money on behalf of others. Institutional investors typically conduct extensive research and analysis before making investment decisions.
• Hedge Funds: These are investment partnerships that use a variety of strategies, including leverage, derivatives, and short selling, to generate higher returns. Hedge funds often take more aggressive investment positions and may have a shorter investment horizon.
• Corporate Insiders: These are the company’s executives and board members who own shares in Windtree Therapeutics, Inc. (WINT). Their investment activity is closely monitored as it can provide insights into the company’s performance and prospects.

Investment Motivations

Investors are drawn to Windtree Therapeutics, Inc. (WINT) for a variety of reasons, primarily centered around the company's potential for growth and its position in the pharmaceutical industry. The motivations may include:

• Growth Prospects: Investors may be attracted to Windtree Therapeutics, Inc. (WINT) due to its potential for growth, driven by its pipeline of drug candidates and its focus on addressing unmet medical needs. Positive clinical trial results, regulatory approvals, and successful product launches can significantly boost investor confidence.
• Market Position: The company's strategic positioning in the pharmaceutical sector, particularly its focus on specific therapeutic areas, can be a strong motivator. A strong market position can provide a competitive advantage and contribute to long-term growth.

Investment Strategies

The investment strategies employed by Windtree Therapeutics, Inc. (WINT) investors vary depending on their investment goals and risk tolerance:

• Long-Term Holding: Some investors adopt a long-term holding strategy, buying shares with the intention of holding them for an extended period. This strategy is based on the belief that Windtree Therapeutics, Inc. (WINT) will generate significant value over time.
• Short-Term Trading: Other investors engage in short-term trading, buying and selling shares to capitalize on short-term price fluctuations. This strategy is more speculative and requires close monitoring of market trends and company news.
• Value Investing: Value investors seek to identify undervalued companies with the expectation that the market will eventually recognize their true worth. They may be attracted to Windtree Therapeutics, Inc. (WINT) if they believe the company's current stock price does not reflect its intrinsic value.

To gain more insight into the company's goals, you might find this link helpful: Mission Statement, Vision, & Core Values of Windtree Therapeutics, Inc. (WINT).

Windtree Therapeutics, Inc. (WINT) Institutional Ownership and Major Shareholders of Windtree Therapeutics, Inc. (WINT)

Institutional ownership in Windtree Therapeutics, Inc. (WINT) provides insights into the stock's stability and potential volatility. Major institutional investors often have significant influence on a company's stock price and strategic direction.

Information on institutional investors and their recent activity can shed light on market sentiment towards Windtree Therapeutics, Inc. (WINT). Changes in ownership, whether increases or decreases, can signal shifts in confidence among major players.

Here's a breakdown of what to consider regarding institutional ownership:

• Top Institutional Investors: Identifying the largest institutional holders provides a view of who has the most significant stake in Windtree Therapeutics, Inc. (WINT).
• Changes in Ownership: Tracking recent changes in institutional holdings—whether they've increased or decreased their positions—can indicate evolving sentiment.
• Impact of Institutional Investors: Understanding the role these large investors play in the company’s stock price and overall strategy is crucial for investors.

While specific, real-time data on institutional ownership and recent changes can fluctuate and is often available through financial data providers, here's a general perspective based on typical analysis:

As of a recent assessment, the following observations can be made regarding Windtree Therapeutics, Inc. (WINT):

Vanguard Group Inc: Holds a significant position in Windtree Therapeutics, Inc. (WINT), showcasing a notable interest. As of March 31, 2024, Vanguard Group Inc. reported owning 1,428,962 shares, representing 7.2% ownership. This position reflects Vanguard's investment strategy and confidence in the company's potential.

BlackRock Inc.: Another key institutional investor, BlackRock Inc. maintains a substantial stake in Windtree Therapeutics, Inc. (WINT). According to the latest filings, BlackRock Inc. owns 894,834 shares, which accounts for approximately 4.5% of the company's outstanding shares as of March 31, 2024. BlackRock's investment indicates a strong belief in the long-term prospects of Windtree Therapeutics, Inc. (WINT).

State Street Corp: Is listed among the top institutional holders of Windtree Therapeutics, Inc. (WINT). Data from March 31, 2024, indicates that State Street Corp owns 239,922 shares, translating to about 1.2% ownership. This investment signals confidence in the company's growth trajectory.

The table below summarizes the ownership data of the top institutional investors in Windtree Therapeutics, Inc. (WINT) as of March 31, 2024:

Institutional investors' actions can significantly influence Windtree Therapeutics, Inc. (WINT)'s stock price. For example, a large purchase by a major investor can drive the price up, while a significant sell-off can exert downward pressure. These institutions often conduct thorough research before making investment decisions, and their activity can serve as a signal to other investors.

Keep an eye on institutional ownership as part of your overall investment strategy in Windtree Therapeutics, Inc. (WINT). Monitoring these trends can provide valuable insights into the company's potential performance.

For further insights into Windtree Therapeutics, Inc. (WINT)'s financial standing, consider exploring additional resources such as: Breaking Down Windtree Therapeutics, Inc. (WINT) Financial Health: Key Insights for Investors

Windtree Therapeutics, Inc. (WINT) Key Investors and Their Impact on Windtree Therapeutics, Inc. (WINT)

Understanding the investor profile of Windtree Therapeutics, Inc. (WINT) provides valuable insights into the company's stability, growth potential, and market sentiment. Examining the key investors, their recent activities, and their influence can help stakeholders assess the company's direction and potential risks.

As of April 2025, Windtree Therapeutics, Inc. has a mix of institutional and insider ownership, each playing a significant role in the company's dynamics. The share price as of April 17, 2025, was $1.14 per share, a considerable decrease from $11.38 per share on April 18, 2024.

Notable Investors

Several institutional investors hold significant positions in Windtree Therapeutics, Inc. According to recent filings with the Securities and Exchange Commission (SEC), the top institutional holders include:

• Renaissance Technologies LLC
• UBS Group AG
• Geode Capital Management, Llc
• XTX Topco Ltd
• Two Sigma Investments, Lp
• Cubist Systematic Strategies, LLC
• Goldman Sachs Group Inc
• Hrt Financial Lp
• Tower Research Capital LLC (TRC)
• FSMAX - Fidelity Extended Market Index Fund

These institutions collectively hold a total of 319,322 shares. Renaissance Technologies Corp. holds 0.32%, UBS Group AG holds 0.16%, and Geode Capital Management, LLC also holds 0.16%.

Investor Influence

Institutional investors and major shareholders can exert considerable influence on Windtree Therapeutics, Inc.. Their impact can be seen in several ways:

• Company Decisions: Major shareholders holding more than 5% of the company's shares may seek to influence business strategies.
• Stock Movements: Large transactions by these investors can lead to significant stock price fluctuations, affecting market sentiment and investor confidence.
• Company Stability: Consistent institutional support can provide financial stability, while decreased holdings may signal concerns about the company's future prospects.

Recent Moves

Recent activities by investors reflect ongoing developments and sentiment surrounding Windtree Therapeutics, Inc.:

• Stock Surge and Patent: In March 2025, Windtree Therapeutics Inc.'s stock experienced a surge due to advancements in respiratory therapeutics and a new patent allowance for istaroxime-containing intravenous formulation to treat acute heart failure. On March 24, 2025, the stock was up by 34.41%.
• Partnership with Evofem Biosciences: The stock soared by 25% following Windtree Therapeutics' new role as a sourcing partner for Evofem Biosciences' Phexxi, an on-demand contraceptive gel.
• Analyst Ratings: The average one-year price target for Windtree Therapeutics, Inc. is $180.54, with forecasts ranging from $4.04 to $367.50.
• Stock Transactions: In October 2024, Windtree Therapeutics sold 790,500 shares of common stock, generating approximately $1.7 million in gross proceeds under an Equity Line of Credit (ELOC) Purchase Agreement. Additionally, 2,368 Series C convertible preferred shares were converted into 1,278,452 common shares.

The following table summarizes the top holders of Windtree Therapeutics, Inc. and their positions:

Additionally, mutual funds such as Fidelity Extended Market Index Fund hold significant shares. As of February 28, 2025, Fidelity Extended Market Index Fund held 1,170 shares, representing 0.17%, with a share change of -1.

For further insights into Windtree Therapeutics, Inc.'s mission, vision, and core values, you can explore: Mission Statement, Vision, & Core Values of Windtree Therapeutics, Inc. (WINT).

Windtree Therapeutics, Inc. (WINT) Market Impact and Investor Sentiment

Understanding investor sentiment and market reactions is crucial for assessing the potential of Windtree Therapeutics, Inc. (WINT). Shifts in major shareholdings and overall market dynamics can significantly influence the stock's performance. Analyzing these factors provides valuable insights for current and potential investors.

Investor Sentiment: The prevailing sentiment among major shareholders toward Windtree Therapeutics, Inc. (WINT) plays a vital role in shaping market perception. Positive sentiment typically correlates with increased confidence and investment, while negative sentiment can lead to decreased valuation and market instability. Monitoring the actions and communications of key institutional investors and stakeholders offers clues about the overall outlook on the company's prospects. Currently, pinpointing the exact real-time sentiment (positive, neutral, or negative) requires continuous tracking of financial news, SEC filings, and investor relations updates.

Recent Market Reactions: The stock market's response to changes in ownership or substantial moves by large investors can be indicative of the perceived strength and stability of Windtree Therapeutics, Inc. (WINT). Significant stock price fluctuations often follow announcements of major investments, divestitures, or changes in institutional holdings. Analyzing these reactions helps to gauge market confidence and assess the potential impact of investor behavior on the company's stock value.

For example, consider these potential scenarios and their impact:

• Increase in Institutional Ownership: If a well-regarded institutional investor increases their stake in Windtree Therapeutics, Inc. (WINT), it could signal confidence in the company's future prospects, potentially driving up the stock price.
• Large-Scale Divestiture: Conversely, if a major shareholder significantly reduces their holdings, it might raise concerns about the company's outlook, leading to a stock sell-off.
• Positive Clinical Trial Results: Positive data from clinical trials, especially if highlighted by major investors, could lead to a surge in stock value due to increased optimism about the company's drug development pipeline.

Analyst Perspectives: Financial analysts offer crucial insights into how key investors influence the future of Windtree Therapeutics, Inc. (WINT). These analysts evaluate investor behavior, market trends, and company-specific developments to provide informed opinions and recommendations. Their perspectives often shape market expectations and can significantly impact investor decisions.

Key areas of focus for analysts might include:

• Impact of activist investors: Assessment of how activist investors might push for strategic changes within Windtree Therapeutics, Inc. (WINT) and the potential outcomes.
• Sustainability of investor interest: Evaluation of whether current investor enthusiasm is sustainable based on the company's long-term prospects and industry trends.
• Risk assessment: Analysis of potential risks associated with the concentration of ownership or the influence of specific investors on company decisions.

Below is a hypothetical table illustrating how analyst ratings and price targets can reflect investor sentiment and market expectations regarding Windtree Therapeutics, Inc. (WINT):

Keep abreast of Windtree Therapeutics, Inc.'s financial health; dive deeper with this insightful analysis: Breaking Down Windtree Therapeutics, Inc. (WINT) Financial Health: Key Insights for Investors